The biotech and pharmaceutical sectors face significant regulatory and operational developments. The FDA reinstated Vinay Prasad as CBER director amid controversy and political pressures. President Trump signed an executive order mandating political appointee oversight of federal research grant approvals, raising concerns about politicization. The FDA proposed stricter policies to restrict export of American citizens’ living cells to foreign labs over data security issues. These moves reflect ongoing shifts impacting scientific governance and the biotech investment landscape.